Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Velichka Valcheva
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Beta
- 1.32
- Country
- IE
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 66.08
Financials
Net Income
$-12.45MEBITDA
$-15.26MFree Cash Flow
$-10.67MEPS (diluted)
$-0.18Shares Outstanding (diluted)
69.17M+147.0%Operating Expenses
$15.35MCash & Debt
$350.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-48.26M | $-0.79 |
| 2024 | $0.00 | $-38.96M | $-0.75 |
| 2023 | $0.00 | $-35.59M | $-0.68 |
| 2022 | $0.00 | $-22.46M | $-0.14 |
| 2021 | $0.00 | $-9.20M | $-0.18 |
| 2020 | $0.00 | $-446.0K | $-0.01 |
| 2019 | $0.00 | $-310.0K | $-0.01 |
Valuation
GHRShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+7.14%Social Signal Score
Mentions (5)
- Newszacks.com·2d ago·Neutral
Wall Street Analysts See a 128.66% Upside in GH Research (GHRS): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 128.7% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
View source ↗ - Newsglobenewswire.com·9d ago·Negative
…cation Cash, cash equivalents and marketable securities of $350.6 million as of September 30, 2026 DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today reported financial results for the quarter ended September 30, 2026, and provided a business update. Business Updates Global Pivotal Program of GH001 in TRD The final resu…
View source ↗ - Newsglobenewswire.com·9d ago·Neutral
GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the appointment of Vanina Popova, MD, as Chief Development Officer, to lead the clinical development of GH001 into our pivotal programs in treatment-resistant depression (TRD)…
View source ↗ - Newsseekingalpha.com·30d ago·Positive
GH Research Remains Undervalued Ahead Of Pivotal Phase III Program GH Research remains significantly undervalued due to the large unmet need in treatment-resistant depression and GH001's potential efficacy. While early data appears promising, and Eli Lilly's acquisition of AtaiBeckley validates the value of 5-MEO-DMT, GH Research still needs to generate solid Phase III data and receive FDA approval. With over 350 million USD in cash, GH Research is well positioned to commercialize GH001. Investo
View source ↗ - Newsseekingalpha.com·63d ago·Neutral
GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities I initiate coverage on GH Research PLC with a "Buy" rating, driven by renewed momentum in its GH001 program for treatment-resistant depression [TRD]. The company resolved the FDA clinical hold on its IND for GH001, positioning it for a pivotal phase 3 TRD trial expected to start in 2026. GH001 demonstrates competitive advantages: shortest-acting psychedelic [11-minute psychoactive phase] and reduced treatment visits
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.27 per share
Typical surprise +20.7% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 13$-0.18 vs $-0.31beat
- Thu, Aug 6$-0.23 vs $-0.29beat
- Thu, May 14$-0.31 vs $-0.27miss
- Thu, Mar 5$-0.23 vs $-0.29beat
- Thu, Nov 6$-0.23 vs $-0.23beat
- Thu, Aug 7$-0.15 vs $-0.22beat
Estimates and results for GHRS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GHRS officers and directors.
No open-market trades in the recent filings. All 40 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
40 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GHRS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
